Erlotinib_Structural_Formulae Tags: Erlotinib View |
Erlotinib hydrochloride (Tarceva) is a drug (medication) used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche.
Verifiedrevid: 364267003
Iupac Name: ''N''-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy),quinazolin-4-amine
Image2: Erlotinib-1m17-3D-balls.png
Casno Ref: cascite
Inchi: 1/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
Inchikey: AAKJLRGGTJKAMG-UHFFFAOYAM
Number on List: 183321-74-6
Chemspiderid: 154044
Atc Prefix: L01
Atc Suffix: XE03
Pubchem: 176870
Drugbank: APRD00951
C: 22 H = 23 N = 3 O = 4
Molecular Weight: 393.436 g/mol
Smiles: n2c1c(cc(OCCOC)c(OCCOC)c1)c(nc2)Nc3cc(C#C)ccc3
Pregnancy Us: D
Legal Uk: POM
Legal Us: Rx-only
Routes Of Administration: Oral
Licence Eu: Tarceva
Licence Us: Erlotinib